Ascorbic Acid

Ascorbic Acid

SCHEMBL408448

CC(=O)[O-].CC(=O)[O-].O=C1O[C@H]([C@@H](O)CO)C(O)=C1O.O=C1O[C@H]([C@@H](O)CO)C(O)=C1O.[Mg+2]

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Ascorbic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.78
LMNA P02545 2/20 0.78
L3MBTL1 Q9Y468 1/20 0.78
HSPD1 P10809 1/20 0.50
HSPE1 P61604 1/20 0.50
TST Q16762 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
TYR P14679 2/20 0.41
MANBA O00462 1/20 0.33
THRB P10828 1/20 0.33
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ascorbic Acid SCHEMBL165191 0.97 MAPT (0.78) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL7086565 0.94 MAPT (0.73) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL29857583 0.94 MAPT (0.83) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL15226289 0.92 MAPT (0.86) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL31356983 0.90 MAPT (0.83) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL28255170 0.90 MAPT (0.83) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL5968922 0.90 MAPT (0.83) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL10642367 0.90 MAPT (0.83) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL10535642 0.89 MAPT (0.76) MAPTLMNAL3MBTL1HSPD1HSPE1
Ascorbic Acid SCHEMBL21372605 0.89 MAPT (0.81) MAPTLMNAL3MBTL1HSPD1HSPE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105025712-B Antimicrobial compositions 西姆莱斯股份公司 2020-05-05 CN disclosed
EP-2414382-B1 BLEACHING PEPTIDES FOR THE ACTIVATION OF THE PROTEASOME AND COMPOSITIONS COMPRISING THEM ISP INVESTMENTS INC (US) 2017-07-12 EP disclosed
EP-2421885-B1 BLEACHING PEPTIDE HYDROLYSATE PROTEASOME ACTIVATOR AND COMPOSITIONS CONTAINING SAME ISP INVESTMENTS INC (US) 2015-02-25 EP disclosed
US-8722627-B2 Proteasome-activating lightening peptidic hydrolyzates and compositions containing them ISP INVESTMENTS INC. (US) 2014-05-13 US disclosed
US-8530623-B2 Proteasome-activating lightening peptides and compositions containing same ISP INVESTMENTS INC. (US) 2013-09-10 US disclosed
US-8309144-B2 Use of a cruciferous protein hydrolysate as a depigmentation agent or for a cosmetic and/or pharmaceutical composition ISP INVESTMENTS INC. (US) 2012-11-13 US disclosed
US-20120100086-A1 BLEACHING PEPTIDE HYDROLYZATE PROTEASOME ACTIVATOR AND COMPOSITIONS CONTAINING SAME AVOCA LLC 2012-04-26 US disclosed
EP-2421885-A1 BLEACHING PEPTIDE HYDROLYSATE PROTEASOME ACTIVATOR AND COMPOSITIONS CONTAINING SAME Isp Investments Inc. (US) 2012-02-29 EP disclosed
EP-2414382-A2 NOVEL PROTEASOME-ACTIVATING LIGHTENING PEPTIDES AND COMPOSITIONS CONTAINING SAME ISP Investments Inc. (US) 2012-02-08 EP disclosed
US-20120020904-A1 NOVEL PROTEASOME-ACTIVATING LIGHTENING PEPTIDES AND COMPOSITIONS CONTAINING SAME PHARMACHEM LABORATORIES LLC 2012-01-26 US disclosed
US-20110158926-A1 Use of a cruciferous protein hydrolysate as a depigmentation agent or for a cosmetic and/or pharmaceutical composition ISP INVESTMENTS INC. (US) 2011-06-30 US disclosed
US-20100322886-A1 USE OF A CRUCIFEROUS PROTEIN HYDROLYSATE AS A DEPIGMENTATION AGENT OR FOR A COSMETIC AND/OR PHARMACEUTICAL COMPOSITION ISP INVESTMENTS INC. 2010-12-23 US disclosed
WO-2010122245-A1 BLEACHING PEPTIDE HYDROLYSATE PROTEASOME ACTIVATOR AND COMPOSITIONS CONTAINING SAME ISP INVESTMENTS INC. (US) 2010-10-28 WO disclosed
WO-2010112711-A2 NOVEL PROTEASOME-ACTIVATING LIGHTENING PEPTIDES AND COMPOSITIONS CONTAINING SAME ISP INVESTMENTS INC. (US) 2010-10-07 WO disclosed
WO-2010112713-A2 NOVEL PROTEASOME-ACTIVATING LIGHTENING PEPTIDES AND COMPOSITIONS CONTAINING SAME ISP INVESTMENTS INC. (US) 2010-10-07 WO disclosed
EP-1776082-B1 USE OF A CRUCIFEROUS PROTEIN HYDROLYSATE AS A DEPIGMENTATION AGENT OR FOR A COSMETIC AND/OR PHARMACEUTICAL COMPOSITION SOC EXTRACTION PRINCIPES ACTIF (FR) 2009-01-21 EP disclosed
US-20070274937-A1 Use of a Cruciferous Protein Hydrolysate as a Depigmentation Agent or For a Cosmetic and/or Pharmaceutical Composition DAL FARRA CLAUDE 2007-11-29 US disclosed
EP-1776082-A1 USE OF A CRUCIFEROUS PROTEIN HYDROLYSATE AS A DEPIGMENTATION AGENT OR FOR A COSMETIC AND/OR PHARMACEUTICAL COMPOSITION SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS SA (VINCIENCE) (FR) 2007-04-25 EP disclosed
WO-2005107697-A1 USE OF A CRUCIFEROUS PROTEIN HYDROLYSATE AS A DEPIGMENTATION AGENT OR FOR A COSMETIC AND/OR PHARMACEUTICAL COMPOSITION SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS SA VINCIENCE (FR) 2005-11-17 WO disclosed